$ARTH
Arch Therapeutics, Inc. Stock $arth

$arth Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-K Financial Statement

#000114420415070409 Filed on December 11, 2015

Income Statement

Concept	2015 Q2	2015	2014 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$810.0K	$3.700M	$860.0K
YoY Change	-2.41%	18.23%
% of Gross Profit
Research & Development	$525.1K	$1.760M	$530.0K
YoY Change	63.92%	19.12%
% of Gross Profit
Depreciation & Amortization		$0.00	$0.00
YoY Change		-100.0%
% of Gross Profit
Operating Expenses	$1.338M	$5.461M	$1.390M
YoY Change	16.74%	18.4%	44.79%
Operating Profit	-$1.338M	-$5.461M
YoY Change	16.74%	18.4%
Interest Expense	$134.3K	$377.8K	$2.020M
YoY Change	383.83%	240.18%
% of Operating Profit
Other Income/Expense, Net			$0.00
YoY Change
Pretax Income	-$770.0K	-$2.948M	$640.0K
YoY Change	-287.8%	-63.79%	-166.67%
Income Tax			$0.00
% Of Pretax Income			0.0%
Net Earnings	-$772.4K	-$2.948M	$640.0K
YoY Change	-288.04%	-63.8%	-166.67%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.02
Diluted Earnings Per Share	-$0.02	-$36.21K	$8.868K
COMMON SHARES
Basic Shares Outstanding	76.80M shares		72.08M shares
Diluted Shares Outstanding	76.80M shares

Balance Sheet

Concept	2015 Q2	2015	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.270M	$3.960M	$830.0K
YoY Change	81.67%	377.12%	48.21%
Cash & Equivalents	$3.274M		$833.5K
Short-Term Investments
Other Short-Term Assets	$40.00K	$42.92K	$40.00K
YoY Change	33.33%	7.3%	100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$3.320M	$4.003M	$877.0K
YoY Change	80.95%	354.89%	-44.39%
LONG-TERM ASSETS
Property, Plant & Equipment			$0.00
YoY Change			-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$0.00
YoY Change			-100.0%
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change			-100.0%
TOTAL ASSETS
Total Short-Term Assets	$3.320M	$4.003M	$877.0K
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$3.320M	$4.003M	$877.0K
YoY Change	80.95%	354.89%	-44.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$500.0K	$231.8K	$175.8K
YoY Change	201.18%	28.76%	-44.14%
Accrued Expenses	$480.0K	$245.5K	$270.0K
YoY Change	118.18%	-9.08%	92.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$500.0K	$473.8K
YoY Change
Total Short-Term Liabilities	$1.890M	$1.286M	$2.724M
YoY Change	-45.38%	-52.72%	497.81%
LONG-TERM LIABILITIES
Long-Term Debt	$960.0K	$966.8K	$960.0K
YoY Change	1.05%	0.71%	2.13%
Other Long-Term Liabilities	$6.530M	$210.0K	$4.090M
YoY Change	22.74%	-94.87%
Total Long-Term Liabilities	$1.147M	$1.177M	$5.046M
YoY Change	-81.72%	-76.7%	434.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.890M	$1.286M	$2.724M
Total Long-Term Liabilities	$1.147M	$1.177M	$5.046M
Total Liabilities	$3.038M	$2.463M	$7.769M
YoY Change	-68.78%	-68.3%	454.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$14.00M		-$12.77M
YoY Change			175.8%
Common Stock	$14.38M		$5.882M
YoY Change	19873.13%		9680.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$279.4K	$1.540M	-$6.892M
YoY Change
Total Liabilities & Shareholders Equity	$3.318M	$4.003M	$877.0K
YoY Change	80.84%	354.89%	-44.75%

Cashflow Statement

Concept	2015 Q2	2015	2014 Q3
OPERATING ACTIVITIES
Net Income	-$772.4K	-$2.948M	$640.0K
YoY Change	-288.04%	-63.8%	-166.67%
Depreciation, Depletion And Amortization		$0.00	$0.00
YoY Change		-100.0%
Cash From Operating Activities	-$820.0K	-$4.239M	-$970.0K
YoY Change	10.81%	26.61%	46.97%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities			$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.520M	7.366M	0.000
YoY Change	-3620.0%	103.48%	-100.0%
NET CHANGE
Cash From Operating Activities	-820.0K	-4.239M	-970.0K
Cash From Investing Activities			0.000
Cash From Financing Activities	3.520M	7.366M	0.000
Net Change In Cash	2.700M	3.127M	-970.0K
YoY Change	-421.43%	-193.37%	-1177.78%
FREE CASH FLOW
Cash From Operating Activities	-$820.0K	-$4.239M	-$970.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	dei	Entity Registrant Name EntityRegistrantName	Arch Therapeutics, Inc.
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001537561
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2015	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015Q1	dei	Entity Public Float EntityPublicFloat	10000000	USD
CY2015Q3	us-gaap	Cash Cash	3960100	USD
CY2014Q3	us-gaap	Cash Cash	833520	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	107392	USD
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	72051	USD
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	17154945	USD
CY2014Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5810200	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15722220	USD
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12774694	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	1540117	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	-6892443	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4003019	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	876990	USD
CY2015Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	473747	USD
CY2014Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2014	us-gaap	Revenues Revenues	0	USD
CY2015	us-gaap	Revenues Revenues	0	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3134285	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3700477	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1477479	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1760037	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	4611764	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	5460514	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-4611764	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-5460514	USD
CY2014	us-gaap	Interest Expense InterestExpense	111059	USD
CY2015	us-gaap	Interest Expense InterestExpense	377805	USD
CY2014	arth	Gain On Exercise Of Warrants GainOnExerciseOfWarrants	0	USD
CY2014	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	0	USD
CY2015	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	1032113	USD
CY2015	arth	Fair Value Of Derivative Liabilities In Excess Of Proceeds FairValueOfDerivativeLiabilitiesInExcessOfProceeds	0	USD
CY2014	arth	Fair Value Of Derivative Liabilities In Excess Of Proceeds FairValueOfDerivativeLiabilitiesInExcessOfProceeds	-7541693	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	1101286	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	1047685	USD
CY2014	arth	Noncash Interest Expense On Notes Payable NoncashInterestExpenseOnNotesPayable	111059	USD
CY2015	arth	Noncash Interest Expense On Notes Payable NoncashInterestExpenseOnNotesPayable	377805	USD
CY2014	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	92500	USD
CY2015	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13779	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-551	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-138937	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	55929	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	126995	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-49194	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3348502	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4239386	USD
CY2014	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1000000	USD
CY2015	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3624703	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	7365966	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	276201	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3126580	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	557319	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	833520	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3960100	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3600000	USD
CY2014	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-4121693	USD
CY2015	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-3536294	USD
CY2014	arth	Change To Gain Or Loss On Warrant Modification ChangeToGainOrLossOnWarrantModification	0	USD
CY2015	arth	Change To Gain Or Loss On Warrant Modification ChangeToGainOrLossOnWarrantModification	-1032113	USD
CY2015	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	750000	USD
CY2014	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2015	us-gaap	Depreciation Depreciation	0	USD
CY2014	us-gaap	Depreciation Depreciation	322	USD
CY2015	arth	Issuance Of Inducement Of Shares IssuanceOfInducementOfShares	135352	USD
CY2014	arth	Issuance Of Inducement Of Shares IssuanceOfInducementOfShares	0	USD
CY2014Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	224000	USD
CY2015Q1	arth	Gain On Warrant Derivative Modification GainOnWarrantDerivativeModification	624016	USD
CY2015	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	451000	USD
CY2015	arth	Stock Issued During Period Inducement Shares StockIssuedDuringPeriodInducementShares	570000	USD
CY2015Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	927373	USD
CY2015Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	454387	shares
CY2015Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.20
CY2013Q2	arth	Increase In Aggregate Number Of Shares IncreaseInAggregateNumberOfShares	3000000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.766	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.194	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0064	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0203	pure
CY2015	arth	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate	0.00	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8637962	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4262500	shares
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-1025000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1098962	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10776500	shares
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	8796959	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10776500	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.38
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.21
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.33
CY2015	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedWeightedAverageRemainingContractualTerm	P0Y
CY2015	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm	P0Y
CY2015	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm	P0Y
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M6D
CY2015	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm	P4Y8M23D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y10M6D
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	335435	USD
CY2015	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue	200668	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	335435	USD
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.36
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.3
CY2015	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	0.32
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.3
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	781506	shares
CY2013Q2	arth	Proceeds From Investors In Contemplation Of Merger ProceedsFromInvestorsInContemplationOfMerger	2000000	USD
CY2013Q2	arth	Unit Issued Price Per Share UnitIssuedPricePerShare	0.50
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.75
CY2013Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2000000	USD
CY2015	us-gaap	Interest Expense Debt InterestExpenseDebt	11000	USD
CY2015Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	966824	USD
CY2014Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	955766	USD
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107542205	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72076487	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72076487	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107542205	shares
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81394873	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67492823	shares
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	187016	USD
CY2014	arth	Stock Issued During Period Value Restricted Stock For Services StockIssuedDuringPeriodValueRestrictedStockForServices	94875	USD
CY2015	arth	Stock Issued During Period Value Restricted Stock For Services StockIssuedDuringPeriodValueRestrictedStockForServices	166157	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	92500	USD
CY2014	arth	Stock Issued During Period Value Private Placement Funding StockIssuedDuringPeriodValuePrivatePlacementFunding	-225297	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1101286	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1047685	USD
CY2015	arth	Stock Issued During Period Value Private Placement Funding StockIssuedDuringPeriodValuePrivatePlacementFunding	3015966	USD
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2731492	USD
CY2015Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	164252	USD
CY2015Q3	arth	Deferred Tax Assets Capitalized Expenditures DeferredTaxAssetsCapitalizedExpenditures	802769	USD
CY2014Q3	arth	Deferred Tax Assets Capitalized Expenditures DeferredTaxAssetsCapitalizedExpenditures	381872	USD
CY2014Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	501175	USD
CY2015Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	124716	USD
CY2015Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5856386	USD
CY2015Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5856386	USD
CY2015Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	1569	USD
CY2014Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	1568	USD
CY2014Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	6230000	USD
CY2014Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	5271000	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2202000	USD
CY2015Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.080	pure
CY2015Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.080	pure
CY2015Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.080	pure
CY2015Q1	us-gaap	Fair Value Assumptions Exercise Price FairValueAssumptionsExercisePrice	0.20
CY2015Q3	us-gaap	Fair Value Assumptions Exercise Price FairValueAssumptionsExercisePrice	0.20
CY2015Q3	us-gaap	Fair Value Assumptions Exercise Price FairValueAssumptionsExercisePrice	0.20
CY2015Q1	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.90	pure
CY2015Q3	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.80	pure
CY2015Q3	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.80	pure
CY2015Q1	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0024	pure
CY2015Q3	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0009	pure
CY2015Q3	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0007	pure
CY2015Q1	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.20	pure
CY2015Q3	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.220	pure
CY2015Q3	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.220	pure
CY2015Q1	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1Y
CY2015Q3	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5M23D
CY2015Q3	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5M16D
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.345
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.345
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.345
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.345
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0
CY2015	arth	Gain On Warrant Derivative Modification GainOnWarrantDerivativeModification	2980829	USD
CY2015	arth	Reclassificationofwarrants Reclassificationofwarrants	3263753	USD
CY2015	arth	Stockissuedduringperiodvaluewarantsexercised Stockissuedduringperiodvaluewarantsexercised	3600000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2015	arth	Stockissuedduringperiodvalueextendingwarrantsandeliminatingratchetprovision Stockissuedduringperiodvalueextendingwarrantsandeliminatingratchetprovision	135352	USD
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	151173	USD
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	151173	USD
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2015	arth	Reclassificationofseriesaandcwarrantsfromderivativeliabilitiestoequity Reclassificationofseriesaandcwarrantsfromderivativeliabilitiestoequity	3263753	USD
CY2014	arth	Reclassificationofseriesaandcwarrantsfromderivativeliabilitiestoequity Reclassificationofseriesaandcwarrantsfromderivativeliabilitiestoequity	0	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	300000	shares
CY2015Q3	us-gaap	Share Price SharePrice	0.35
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	150000	shares
CY2015	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-166157	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-94875	USD
CY2015	arth	License Maintenance Costs LicenseMaintenanceCosts	45000	USD
CY2014	arth	License Maintenance Costs LicenseMaintenanceCosts	35000	USD
CY2015Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2015Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1146560	USD
CY2015Q2	us-gaap	Liabilities Liabilities	3038449	USD
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	14288150	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14001900	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	279406	USD
CY2015Q2	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	565844	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2636785	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-772385	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1227206	USD
CY2015Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-302524	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	3546924	USD
CY2015	arth	Convertible Note Embedded Of Convertible Beneficial Conversion Feature ConvertibleNoteEmbeddedOfConvertibleBeneficialConversionFeature	354988	USD
CY2014	arth	Convertible Note Embedded Of Convertible Beneficial Conversion Feature ConvertibleNoteEmbeddedOfConvertibleBeneficialConversionFeature	0	USD

Files In Submission

Name	View Source	Status
0001144204-15-070409-index-headers.html	Edgar Link	pending
0001144204-15-070409-index.html	Edgar Link	pending
0001144204-15-070409.txt	Edgar Link	pending
0001144204-15-070409-xbrl.zip	Edgar Link	pending
arth-20150930.xml	Edgar Link	completed
arth-20150930.xsd	Edgar Link	pending
arth-20150930_cal.xml	Edgar Link	unprocessable
arth-20150930_def.xml	Edgar Link	unprocessable
arth-20150930_lab.xml	Edgar Link	unprocessable
arth-20150930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v425708_10k.htm	Edgar Link	pending
v425708_ex23-1.htm	Edgar Link	pending
v425708_ex31-1.htm	Edgar Link	pending
v425708_ex31-2.htm	Edgar Link	pending
v425708_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARTH
Arch Therapeutics, Inc. Stock $arth

2015 Q2 Form 10-K Financial Statement

#000114420415070409 Filed on December 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH Arch Therapeutics, Inc. Stock $arth

2015 Q2 Form 10-K Financial Statement

#000114420415070409 Filed on December 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH
Arch Therapeutics, Inc. Stock $arth